FDC Limited
Preview the depth — unlock the full forensic study.
You're reading the free Overview. The full Landscape study, the Lenses, governance and quality scans unlock with Pro — across 5,000 Indian companies.
Briefing
FDC Limited — the brief
Forensic posture: Material flags. The auditor gave an unqualified opinion but flagged two medium-severity control gaps: audit-trail weakness at the database level and ₹11,409.79 lakhs in disputed statutory dues across multiple jurisdictions; related-party dealings show a worrying subsidiary loan that was impaired then written off, and ₹405.66 lakhs in inter-company receivables, though most other transactions are routine; contingent liabilities stand at ₹9,962.25 lakhs (4.4% of net worth, chiefly a ₹7,172.93 lakhs income tax demand under appeal), and the company's earnings quality is solid (composite 87/100) with strong profitability metrics and low bankruptcy risk.
Auditor’s report (CARO 2020)
Auditor’s assessment Material flags. Auditor: B S R & Co. LLP. Opinion: Unqualified. Fiscal year FY24-25. 0 critical, 2 material, 0 minor flags.
- Audit trail not enabled at database level: The Company's accounting software lacks full audit trail functionality at the database level, which is a control weakness that could allow undetected data modifications.
- Disputed statutory dues pending resolution: The Company has significant disputed tax and statutory liabilities totalling over ₹11,409.79 lakhs across multiple jurisdictions and statutes, with substantial amounts not yet deposited pending resolution of disputes.
Related-party transactions
Assessment Concerning. 28 related parties disclosed. Fiscal year FY25.
- Subsidiary loan with impairment recorded: Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd. had no outstanding loan as at 31st March 2025, but prior year showed impairment of loan indicating potential fund diversion or credit concern.
- Interest income from subsidiary stopped: Interest income from Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd. ceased in FY2025 after ₹124.89 lakhs in prior year, suggesting loan status change or restructuring.
- Material trade receivable from subsidiary: Outstanding trade receivable of ₹405.66 lakhs from FDC International Limited (FY2024: ₹476.79 lakhs) represents significant inter-company balance.
Contingent liabilities
Assessment Notable. Total disclosed: ₹9,962 Cr (4.4% of net worth). Fiscal year FY24-25.
- Income tax demand under appeal by Company
Corporate governance
Board of 10 directors, 50% independent. Chair: CA. Uday Kumar Gurkar. Chair and CEO roles are separated. Statutory auditor: B S R & Co. LLP. Board remuneration: 5.3% of net profit. Fiscal year FY24-25.
“The Company has recorded for impairment of loan given to Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd. as ₹ Nil for the year ended 31st March, 2025”
What retail misses·The database audit-trail gap is a governance red flag that won't show up in earnings headlines or stock screener alerts but indicates weak internal financial controls; the subsidiary loan write-off and cessation of interest income hint at a troubled overseas entity that is buried in the related-party disclosures and contingent liabilities schedules.
Strengths noted in disclosures: Earnings quality composite score of 87/100 with excellent ratings on Sloan accruals and Novy-Marx profitability; Altman Z-score of 11.27 places the company in safe zone with minimal bankruptcy risk. · Related-party transaction disclosures are detailed; KMP remuneration of ₹1,576.85 lakhs is within statutory limits and properly disclosed. · Contingent liabilities at 4.4% of net worth are manageable; the largest item (₹7,172.93 lakhs income tax demand) is already under appeal in court and would only crystallize if the company loses the case.
Forensic signal
From the company's own filingsBalanced profile — no axis is significantly above or below the median.